Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
This Phase 3 study has been designed to confirm that adding custirsen to
cabazitaxel/prednisone treatment can slow tumor progression and enhance survival outcomes
compared to standard cabazitaxel/prednisone treatment in men with metastatic castrate
resistant prostate cancer (CRPC). This will be a randomized, open-label, multicenter,
international trial. Treatment will consist of cabazitaxel/prednisone/custirsen vs.
cabazitaxel/prednisone. A total of approximately 630 patients will be randomized with equal
probability to the two arms.